Why Moderna, Inc. (MRNA) stock moved
Moderna, Inc. (MRNA) shares tumbled 7.8% to $218.01 as of October 18, 2026, a significant decline from the prior close of $236.50. BestStocks flagged the session as a major change for MRNA. Below, we break down what changed for MRNA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MRNA fell 7.8% to $218.01
MRNA tumbled 7.8% in its latest session, moving from $236.50 to $218.01.
What it means for Moderna, Inc. investors
For Moderna, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Moderna rallied 6.10% to $201.60 on index inclusion momentum and pipeline optimism. Weighing against that: Sharp 7.8% decline — elevated risk; Moderna pulled back 6.23% to $190.56 after hitting a 52-week intraday high of $212.22, driven by profit-taking and a sector-wide vaccine stock cooldown following World Health Organization risk updates that dampened speculative momentum. Wall Street's consensus price target sits at $117.40, implying -46.1% downside from $218.01. Over the past 90 days analysts logged 3 upgrades and 2 downgrades. BestStocks rates the overall signal quality medium (61/100). With earnings roughly 19 days out, the next report is the most likely near-term test of the move.
MRNA price reaction
MRNA last traded at $218.01, down $18.49 (-7.82%) from the previous close of $236.50. The session traded on 1.3× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $154.04 and $236.50, and it currently sits about 78% of the way up that band.
Bullish and bearish analyst opinions on Moderna, Inc. (MRNA)
The consensus analyst price target on Moderna, Inc. (MRNA) is $117.40, 46.1% below the recent $218.01. Over the past 90 days analysts logged 3 upgrades, 9 maintains, and 2 downgrades. Here is how the bullish and bearish cases on MRNA line up.
The bullish case
- The Street's most bullish target is $245.00 (+12.4%).
- 3 analyst upgrades in the past 90 days, most recently Argus Research to Buy (2026-08-28).
- Positive price momentum.
- Moderna rallied 6.10% to $201.60 on index inclusion momentum and pipeline optimism.
The bearish case
- The consensus analyst price target of $117.40 sits 46.1% below the recent $218.01, so the average target sees limited room to run.
- The most bearish analyst target is $25.00 (-88.5%).
- 2 analyst downgrades in the past 90 days, most recently Citigroup to Sell (2026-09-30).
- Sharp 7.8% decline — elevated risk.
- Moderna pulled back 6.23% to $190.56 after hitting a 52-week intraday high of $212.22, driven by profit-taking and a sector-wide vaccine stock cooldown following World Health Organization risk updates that dampened speculative momentum.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 18, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MRNA
In-depth MRNA event analyses
Frequently asked questions about MRNA
Why did Moderna, Inc. (MRNA) stock move?
MRNA tumbled 7.8% to $218.01. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MRNA stock fall?
MRNA lost 7.82% ($18.49) versus the prior close of $236.50, last trading at $218.01 on 1.3× average volume.
When is Moderna, Inc.'s next earnings date?
MRNA's next earnings report is estimated for 2026-11-06 — about 19 days away.
What is the analyst price target for MRNA?
The consensus analyst price target for MRNA is $117.40, about 46.1% below the current $218.01. Over the past 90 days, analysts recorded 3 upgrades, 9 maintains, and 2 downgrades.
How BestStocks tracks MRNA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRNA-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MRNA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 18, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
